Treatment with nintedanib, a tyrosine kinase inhibitor, slowed the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc) in a 52-week randomized placebo-controlled trial. The adjusted annual rate of decline in forced vital capacity was lower in the nintedanib-treated group than in the placebo-treated group (P = 0.04), although no clinical benefits for other manifestations of SSc were observed. The adverse-event profile was similar to that reported in previous trials of patients with idiopathic pulmonary fibrosis; the rate of gastrointestinal adverse events, including diarrhoea, was higher in the nintedanib group than in the placebo group.
References
Original article
Distler, O. et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1903076 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. Nintedanib slows ILD progression in SSc. Nat Rev Rheumatol 15, 384 (2019). https://doi.org/10.1038/s41584-019-0247-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0247-1